In this series, we’re exploring how we use our defining edge to bring clarity and credibility to policy debates. Most of us pay our health insurance premiums so that if we do get sick or injured, the treatments our doctors prescribe will be covered. But increasingly, that coverage is coming with high out-of-pocket costs.

In this series, we’re exploring how we use our defining edge to bring clarity and credibility to policy debates. As the debate on “Most Favored Nation” policies started to heat up last year, No Patient Left Behind delivered issue briefs and comment letters that helped media and regulators better understand this policy’s risks. We also used analyses to share our concerns about the Inflation Reduction Act’s pill penalty.

In this series, we’re exploring how we use our defining edge to bring clarity and credibility to policy debates. When FDA capabilities and NIH funding first came under threat last year, No Patient Left Behind activated our network to gather real-time, actionable insights.

If we systematically undervalue medicine, we’ll under-invest in future innovation, which means we’ll end up with fewer of the breakthroughs we desperately need. That leaves us all worse off. Let's stop overlooking elements of value. The transplant that changed my life is proof that investing in innovation pays dividends for patients, for caregivers, for the health care system, and for all of us.

For people living with chronic disease, health insurance shouldn’t be another hurdle. We should spend our energy and focus fighting for the best lives we can, not fighting against insurance companies. To learn more about how to #FixInsurance so it works as it should, visit https://www.nopatientleftbehind.org/fixinsurance.

My kidneys started failing when I was just five years old. Decades later, ongoing innovation has kept me alive. This National Kidney Month, let’s celebrate progress and push for policies that ensure treatment advances are affordable and accessible. Learn more at https://www.nopatientleftbehind.org/protect-innovation.

In her first message as Executive Director, Priscilla VanderVeer discusses No Patient Left Behind’s commitment to patient access, innovation, and policy credibility.

Our modern world needs a modern Food and Drug Administration (FDA). As PDUFA VIII offers a historic opportunity to make the drug review program faster, more consistent, and more transparent, here are a few suggestions we heard from our network of experts.

Here are five policies President Biden should include in his State of the Union address on Thursday.

Read what one oncology executive discovered when he surveyed the biotech community.